Peer-review started: January 28, 2015
First decision: March 6, 2015
Revised: March 16, 2015
Accepted: April 8, 2015
Article in press: April 9, 2015
Published online: May 2, 2015
Processing time: 91 Days and 9 Hours
Core tip: Mycosis fungoides and Sézary syndrome are characterized by a clonal expansion of malignant CD4+ T lymphocytes with skin-homing properties. Currently, treatment options for mycosis fungoides and Sézary syndrome are limited. The lack of effective targeted therapy results in part from the poor understanding regarding the pathophysiology of these diseases. Recently, a number of chemokines and chemokine receptors have been found to contribute to the pathogenesis of mycosis fungoides and Sézary syndrome, including the CC chemokine receptor 4 (CCR4)/chemokine (C-C motif) ligand 17 (CCL17), CCR10/CCL27, C-X-C chemokine receptor type 4/chemokine (C-X-C Motif) ligand 12 and CCR7/CCL21 axes. Therefore, these chemokines and chemokine receptors may be potentially useful targets for the treatment of these lymphomas in the future.